← Back to Screener
Vir Biotechnology, Inc. Common Stock (VIR)
Price$11.09
Favorite Metrics
Price vs S&P 500 (26W)76.60%
Price vs S&P 500 (4W)8.64%
Market Capitalization$1.72B
All Metrics
Book Value / Share (Quarterly)$5.49
P/TBV (Annual)1.11x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-65.12%
Cash Flow / Share (Quarterly)$-2.84
Price vs S&P 500 (YTD)74.14%
Gross Margin (TTM)99.96%
Net Profit Margin (TTM)-638.87%
EPS (TTM)$-3.16
10-Day Avg Trading Volume1.92M
EPS Excl Extra (TTM)$-3.16
Revenue Growth (5Y)-2.14%
EPS (Annual)$-3.16
ROI (Annual)-57.23%
Gross Margin (Annual)99.96%
Net Profit Margin (5Y Avg)-395.16%
Cash / Share (Quarterly)$3.35
Revenue Growth QoQ (YoY)417.78%
ROA (Last FY)-43.68%
Revenue Growth TTM (YoY)-7.61%
EBITD / Share (TTM)$-3.38
ROE (5Y Avg)-15.91%
Operating Margin (TTM)-699.18%
Cash Flow / Share (Annual)$-2.84
P/B Ratio2.24x
P/B Ratio (Quarterly)1.10x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)21.67x
Net Interest Coverage (TTM)10.09x
ROA (TTM)-38.74%
EV / EBITDA (TTM)1.76x
EPS Incl Extra (Annual)$-3.16
Current Ratio (Annual)5.54x
Quick Ratio (Quarterly)5.09x
3-Month Avg Trading Volume3.01M
52-Week Price Return97.79%
EV / Free Cash Flow (Annual)-2.40x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$5.43
P/S Ratio (Annual)25.06x
Asset Turnover (Annual)0.07x
52-Week High$10.94
Operating Margin (5Y Avg)-438.90%
EPS Excl Extra (Annual)$-3.16
CapEx CAGR (5Y)-5.76%
Tangible BV CAGR (5Y)2.09%
26-Week Price Return85.34%
Quick Ratio (Annual)5.09x
13-Week Price Return57.62%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)5.54x
Enterprise Value$1,485.787
Revenue / Share Growth (5Y)-5.04%
Asset Turnover (TTM)0.06x
Book Value / Share Growth (5Y)-0.50%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-638.56%
Cash / Share (Annual)$3.35
3-Month Return Std Dev86.34%
Gross Margin (5Y Avg)96.11%
Net Income / Employee (TTM)$-1
ROE (Last FY)-57.23%
Net Interest Coverage (Annual)11.83x
EPS Basic Excl Extra (Annual)$-3.16
P/FCF (TTM)1.08x
Receivables Turnover (TTM)4.18x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-3.16
Receivables Turnover (Annual)4.18x
ROI (TTM)-49.31%
P/S Ratio (TTM)25.06x
Pretax Margin (5Y Avg)-395.11%
Revenue / Share (Annual)$0.49
Tangible BV / Share (Annual)$5.43
Price vs S&P 500 (52W)62.70%
Year-to-Date Return78.28%
5-Day Price Return15.47%
EPS Normalized (Annual)$-3.16
ROA (5Y Avg)-13.52%
Net Profit Margin (Annual)-638.87%
Month-to-Date Return19.98%
Cash Flow / Share (TTM)$-4.36
EBITD / Share (Annual)$-3.46
Operating Margin (Annual)-699.18%
ROI (5Y Avg)-15.91%
EPS Basic Excl Extra (TTM)$-3.16
P/TBV (Quarterly)1.11x
P/B Ratio (Annual)1.10x
Pretax Margin (TTM)-638.56%
Book Value / Share (Annual)$5.49
Price vs S&P 500 (13W)54.76%
Beta1.77x
P/FCF (Annual)1.08x
Revenue / Share (TTM)$0.49
ROE (TTM)-49.31%
52-Week Low$4.16
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
4.21
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
VIRVir Biotechnology, Inc. Common Stock | 25.06x | -7.61% | 99.96% | — | $11.09 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Vir Biotechnology is a clinical-stage biopharmaceutical company developing immunology-focused medicines for serious infectious diseases and cancer. The company leverages proprietary technologies including antibody engineering, an AI discovery platform (dAIsY), and a masking platform (PRO-XTEN) to develop a pipeline that includes therapies for hepatitis delta virus and HIV, as well as multiple solid tumor programs. Currently, the company generates revenue primarily through licensing agreements and research grants while advancing its clinical development programs.